Related references
Note: Only part of the references are listed.Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up
Robert J. Kreitman et al.
BLOOD (2018)
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Michael R. Grever et al.
BLOOD (2017)
Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis
Victoria Divino et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2017)
How I manage patients with hairy cell leukaemia
Philip A. Thompson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Hairy cell leukemia: Past, present and future
Bartlomiej M. Getta et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2015)
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
E. Tiacci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series
Joshua D. Rosenberg et al.
BLOOD (2014)
Hairy cell leukemia: Update on molecular profiling and therapeutic advances
Michael R. Grever et al.
BLOOD REVIEWS (2014)
Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Mauricio Burotto et al.
CLINICAL CANCER RESEARCH (2013)
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia
Farhad Ravandi et al.
BLOOD (2011)
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2011)
Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping
Martin S. Tallman
LEUKEMIA & LYMPHOMA (2011)
Hairy Cell Leukemia Evaluation of the Long-Term Outcome in 121 Patients
Pier Luigi Zinzani et al.
CANCER (2010)
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
Monica Else et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab
Maria K. Angelopoulou et al.
LEUKEMIA & LYMPHOMA (2008)
Eradication of minimal residual disease in hairy cell leukemia
F Ravandi et al.
BLOOD (2006)
Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia
J Nieva et al.
BLOOD (2003)
Rituximab in relapsed or refractory hairy cell leukemia
DA Thomas et al.
BLOOD (2003)
Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia
H Hagberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
RJ Kreitman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
